我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
20
9 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
2
10.0%
已完成
9
45.0%
尚未招募
7
35.0%
招募中
暂无批准数据
- BlinkLab Limited has initiated its FDA registrational trial for an AI-powered smartphone-based autism diagnostic tool at PriMED Clinical Research in Dayton, Ohio, targeting recruitment of 1,000 participants. - The innovative diagnostic platform aims to enable autism detection in children as young as 18 months, significantly earlier than traditional diagnosis methods that typically occur around age five. - The study will begin with an initial 100-patient phase, targeting 15-20 enrollments monthly, marking a crucial step toward FDA approval of the BlinkLab Dx 1 diagnostic tool.
